Key result
Small, dense LDL affects >76% of Japanese diabetics with coronary heart disease and its size can be increased by weight reduction, antidiabetic agents, statins, and fibrates.
Why the study?
What are the clinical associations of small dense LDL and which treatments can increase LDL size?
What are the clinical associations of small dense LDL and which treatments can increase LDL size?
Small dense LDL is a marker of atherogenic dyslipidemia prevalent in various metabolic conditions, and its size can be favorably modified by lifestyle and pharmacological interventions.
Answers are grounded in this paper and cite their sources.
Small dense LDL frequency was associated with CHD risk in Japanese diabetics; hypothesis-generating for targeted interventions.
The increased frequency of small, dense LDL is associated with the risk of coronary heart disease (CHD). Possible mechanisms include the increased susceptibility of small, dense LDL to oxidation and its high affinity for LDL-receptor-independent cell surface binding sites. Although more than 30% of adult men in the USA have been reported to have small,dense LDL, only 5.4% of young Japanese men are affected. However, more than 76% of Japanese diabetics with coronary heart disease have small, dense LDL. Furthermore, almost half of all obese women (BMI > 35 kg/m(2)) have small, dense LDL. Our previous observation revealed that type 2 diabetics had smaller LDL even if they were apparently normolipidemic. In the normotriglycelidemic group there was also a close relationship between LDL size and plasma triglyceride. Diabetics with microalbuminuria had smaller LDL than those with normoalbuminuria, indicating the early nephrotoxicity of small, dense LDL. We also found that young men with high-normal blood pressure have smaller LDL than those with optimal blood pressure. Furthermore, LDL size was decreased not only in preeclamptic women but also in normal pregnant women. Finally, weight reduction by obese women through strict diet control, the treatment of diabetics by acarbose or troglitazone, and the treatment of hyperlipidemia by new statins as well as fibrates were all successful in increasing LDL size associated with decreased plasma triglyceride.
No takes yet. Share an insight, caveat, or question.
Yoshino et al. (2002) conducted a review in Small dense LDL and coronary heart disease. Weight reduction, antidiabetic agents, statins, and fibrates was evaluated. Small, dense LDL affects >76% of Japanese diabetics with coronary heart disease and its size can be increased by weight reduction, antidiabetic agents, statins, and fibrates.
Synapse has enriched 10 related papers. Consider them for comparative context: